CA2663332C - Iminoimidazopyridine derivatives having antithrombotic activity - Google Patents

Iminoimidazopyridine derivatives having antithrombotic activity Download PDF

Info

Publication number
CA2663332C
CA2663332C CA2663332A CA2663332A CA2663332C CA 2663332 C CA2663332 C CA 2663332C CA 2663332 A CA2663332 A CA 2663332A CA 2663332 A CA2663332 A CA 2663332A CA 2663332 C CA2663332 C CA 2663332C
Authority
CA
Canada
Prior art keywords
alkylene
alkyl
formula
het
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2663332A
Other languages
English (en)
French (fr)
Other versions
CA2663332A1 (en
Inventor
Uwe Heinelt
Armin Hofmeister
Joerg Czech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CA2663332A1 publication Critical patent/CA2663332A1/en
Application granted granted Critical
Publication of CA2663332C publication Critical patent/CA2663332C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2663332A 2006-08-02 2007-07-18 Iminoimidazopyridine derivatives having antithrombotic activity Expired - Fee Related CA2663332C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006036023.0 2006-08-02
DE102006036023A DE102006036023A1 (de) 2006-08-02 2006-08-02 Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
PCT/EP2007/006360 WO2008014888A2 (de) 2006-08-02 2007-07-18 Imino-imidazo-pyridinderivate mit antithrombotischer aktivität

Publications (2)

Publication Number Publication Date
CA2663332A1 CA2663332A1 (en) 2008-02-07
CA2663332C true CA2663332C (en) 2015-06-02

Family

ID=38884850

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2663332A Expired - Fee Related CA2663332C (en) 2006-08-02 2007-07-18 Iminoimidazopyridine derivatives having antithrombotic activity

Country Status (23)

Country Link
US (1) US7863269B2 (cg-RX-API-DMAC7.html)
EP (1) EP2054412B1 (cg-RX-API-DMAC7.html)
JP (1) JP5149897B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090129981A (cg-RX-API-DMAC7.html)
CN (1) CN101495478B (cg-RX-API-DMAC7.html)
AR (1) AR062158A1 (cg-RX-API-DMAC7.html)
AT (1) ATE450537T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007280780B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663332C (cg-RX-API-DMAC7.html)
CL (1) CL2007002240A1 (cg-RX-API-DMAC7.html)
DE (2) DE102006036023A1 (cg-RX-API-DMAC7.html)
DK (1) DK2054412T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2007000120A (cg-RX-API-DMAC7.html)
ES (1) ES2336044T3 (cg-RX-API-DMAC7.html)
IL (1) IL196789A (cg-RX-API-DMAC7.html)
MX (1) MX2009000408A (cg-RX-API-DMAC7.html)
MY (1) MY148611A (cg-RX-API-DMAC7.html)
NO (1) NO20090741L (cg-RX-API-DMAC7.html)
PE (1) PE20080687A1 (cg-RX-API-DMAC7.html)
PT (1) PT2054412E (cg-RX-API-DMAC7.html)
TW (1) TWI400240B (cg-RX-API-DMAC7.html)
WO (1) WO2008014888A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152040A (en) * 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5124517B1 (cg-RX-API-DMAC7.html) 1971-03-15 1976-07-24
DE2221796A1 (de) 1972-05-04 1973-11-15 Kraemer Kg Wilhelm Batteriebehaelter fuer stabbatterien
JPS60161986A (ja) * 1983-12-24 1985-08-23 Nippon Soda Co Ltd イミダゾ(1,5−a)ピリジン−3−オン誘導体及びその製造方法
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
RU2270192C2 (ru) * 2001-04-19 2006-02-20 Эйсай Ко., Лтд. Производные 2-иминопирролидина
EP1982984B1 (en) 2002-04-16 2013-02-13 Merck Sharp & Dohme Corp. Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
EP1602646A4 (en) 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd PROCESS FOR PREPARING CYCLIC BENZAMIDINE DERIVATIVES
DE10353205A1 (de) 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen
US7317124B2 (en) 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates

Also Published As

Publication number Publication date
KR20090129981A (ko) 2009-12-17
US7863269B2 (en) 2011-01-04
PT2054412E (pt) 2010-02-04
CN101495478A (zh) 2009-07-29
DK2054412T3 (da) 2010-04-19
NO20090741L (no) 2009-02-16
WO2008014888A3 (de) 2008-06-12
DE102006036023A1 (de) 2008-02-07
TWI400240B (zh) 2013-07-01
US20090192150A1 (en) 2009-07-30
ES2336044T3 (es) 2010-04-07
JP2009545542A (ja) 2009-12-24
DE502007002219D1 (de) 2010-01-14
TW200821308A (en) 2008-05-16
JP5149897B2 (ja) 2013-02-20
EP2054412A2 (de) 2009-05-06
MY148611A (en) 2013-05-15
AR062158A1 (es) 2008-10-22
MX2009000408A (es) 2009-01-27
AU2007280780A1 (en) 2008-02-07
HK1135694A1 (en) 2010-06-11
IL196789A0 (en) 2009-11-18
IL196789A (en) 2012-07-31
PE20080687A1 (es) 2008-07-24
CA2663332A1 (en) 2008-02-07
CN101495478B (zh) 2013-03-27
AU2007280780B2 (en) 2012-03-29
BRPI0714599A2 (pt) 2013-04-09
WO2008014888A2 (de) 2008-02-07
ATE450537T1 (de) 2009-12-15
CL2007002240A1 (es) 2008-02-08
DOP2007000120A (es) 2008-02-29
EP2054412B1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
US8466169B2 (en) SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments
AU2007297013B2 (en) Isoserine derivatives for use as coagulation factor IXa inhibitors
AU2009211890B2 (en) Imidazopyridazines as PAR1 inhibitors, production thereof, and use thereof as medicaments
JP4733648B2 (ja) マトリックスメタロプロテイナーゼ阻害剤としての使用のためのチエノ−イミノ酸誘導体
JP5249225B2 (ja) 凝固第IXa因子インヒビターとしての使用のための酒石酸誘導体
AU2007280780B2 (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
JP4861179B2 (ja) マトリックスメタロプロテイナーゼの阻害剤として使用される二環式イミノ酸誘導体
JP4871273B2 (ja) 4−トリフルオロメトキシフェノキシベンゾール−4’−スルホン酸、その製造法および薬剤としての使用
KR101315788B1 (ko) 매트릭스 메탈로프로테이나제의 억제제로서 사용하기 위한테트라하이드로푸란 유도체
HK1135694B (en) Imino-imidazo-pyridine derivatives having antithrombotic activity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190718